Cigna stock jumps as earnings beat meets soft 2026 outlook and FTC insulin settlement
Cigna shares rose 3.2% to $280.46 after posting Q4 adjusted earnings of $8.08 per share, above forecasts, though its 2026 outlook missed estimates. Express Scripts agreed to a 10-year FTC settlement on insulin pricing, expected to cut patient costs by up to $7 billion. Evernorth pharmacy revenue jumped 20% to $36.3 billion. Cigna’s board raised its quarterly dividend to $1.56 per share.